These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36110857)
1. Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption. Pace M; Ogbe A; Hurst J; Robinson N; Meyerowitz J; Olejniczak N; Thornhill JP; Jones M; Waters A; Lwanga J; Kuldanek K; Hall R; Zacharopoulou P; Martin GE; Brown H; Nwokolo N; Peppa D; Fox J; Fidler S; Frater J Front Immunol; 2022; 13():878743. PubMed ID: 36110857 [TBL] [Abstract][Full Text] [Related]
4. Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. Poonia B; Pauza CD PLoS One; 2014; 9(2):e88884. PubMed ID: 24520422 [TBL] [Abstract][Full Text] [Related]
5. Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset. Mantegani P; Tambussi G; Galli L; Din CT; Lazzarin A; Fortis C Immunology; 2010 Feb; 129(2):220-33. PubMed ID: 19824914 [TBL] [Abstract][Full Text] [Related]
6. NKG2C+ natural killer cell function improves the control of HBV replication in individuals with acute HIV infection coinfected with HBV. Song T; Li L; Su B; Liu L; Liu Y; Yang X; Zhang Q; Guo N; Zhang T; Sun G; Wu H Medicine (Baltimore); 2020 May; 99(18):e20073. PubMed ID: 32358389 [TBL] [Abstract][Full Text] [Related]
7. Immune Dysfunctions of CD56 Cao WJ; Zhang XC; Wan LY; Li QY; Mu XY; Guo AL; Zhou MJ; Shen LL; Zhang C; Fan X; Jiao YM; Xu RN; Zhou CB; Yuan JH; Wang SQ; Wang FS; Song JW Front Immunol; 2021; 12():811091. PubMed ID: 35069597 [TBL] [Abstract][Full Text] [Related]
8. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection. Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913 [TBL] [Abstract][Full Text] [Related]
9. Early antiretroviral therapy and its impact on natural killer cell dynamics in HIV-1 infected men who have sex with men: a cross-sectional pilot study evaluating the impact of early ART initiation on NK cell perturbation in HIV infection. Akiso M; Muema D; Langat R; Naidoo KK; Oino G; Mutua G; Thobakgale C; Ochiel D; Chinyenze K; Anzala O; Mureithi MW Microbiol Spectr; 2024 Apr; 12(4):e0357023. PubMed ID: 38364104 [TBL] [Abstract][Full Text] [Related]
10. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda. Naluyima P; Eller MA; Laeyendecker O; Quinn TC; Serwadda D; Sewankambo NK; Gray RH; Michael NL; Wabwire-Mangen F; Robb ML; Sandberg JK AIDS; 2014 Jun; 28(9):1273-8. PubMed ID: 24959961 [TBL] [Abstract][Full Text] [Related]
11. Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56(dim) and CD56(bright) cells and memory-like CD57⁺NKG2C⁺CD56(dim) cells. Lima JF; Oliveira LM; Pereira NZ; Mitsunari GE; Duarte AJ; Sato MN J Acquir Immune Defic Syndr; 2014 Dec; 67(5):463-71. PubMed ID: 25230289 [TBL] [Abstract][Full Text] [Related]
12. Control of the HIV-1 DNA Reservoir Is Associated Marras F; Casabianca A; Bozzano F; Ascierto ML; Orlandi C; Di Biagio A; Pontali E; Dentone C; Orofino G; Nicolini L; Taramasso L; Magnani M; Marincola FM; Wang E; Moretta L; De Maria A J Virol; 2017 Dec; 91(23):. PubMed ID: 28956765 [TBL] [Abstract][Full Text] [Related]
13. Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort. Nabatanzi R; Bayigga L; Cose S; Rowland-Jones S; Canderan G; Joloba M; Nakanjako D Clin Immunol; 2019 Apr; 201():55-60. PubMed ID: 30817998 [TBL] [Abstract][Full Text] [Related]
14. Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial. Alagaratnam J; Stöhr W; Hamlyn E; Porter K; Toombs J; Heslegrave A; Zetterberg H; Gisslén M; Underwood J; Schechter M; Kaleebu P; Tambussi G; Kinloch S; Miro JM; Kelleher AD; Babiker A; Frater J; Winston A; Fidler S; J Virus Erad; 2024 Jun; 10(2):100381. PubMed ID: 38988673 [TBL] [Abstract][Full Text] [Related]
15. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185 [TBL] [Abstract][Full Text] [Related]
16. Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort). Doria M; Zicari S; Cotugno N; Domínguez-Rodríguez S; Ruggiero A; Pascucci GR; Tagarro A; Rojo Conejo P; Nastouli E; Gärtner K; Cameron M; Richardson B; Foster C; Williams SL; Rinaldi S; De Rossi A; Giaquinto C; Rossi P; Pahwa S; Palma P; J Int AIDS Soc; 2021 Jul; 24(7):e25717. PubMed ID: 34235857 [TBL] [Abstract][Full Text] [Related]
17. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Titanji K; Sammicheli S; De Milito A; Mantegani P; Fortis C; Berg L; Kärre K; Travi G; Tassandin C; Lopalco L; Rethi B; Tambussi G; Chiodi F Immunology; 2008 Feb; 123(2):164-70. PubMed ID: 17627773 [TBL] [Abstract][Full Text] [Related]
18. Decreased CD122 on CD56 Han W; Ni Q; Liu K; Yao Y; Zhao D; Liu X; Chen Y Life Sci; 2018 Feb; 195():53-60. PubMed ID: 29307521 [TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Ivison GT; Vendrame E; Martínez-Colón GJ; Ranganath T; Vergara R; Zhao NQ; Martin MP; Bendall SC; Carrington M; Cyktor JC; McMahon DK; Eron J; Jones RB; Mellors JW; Bosch RJ; Gandhi RT; Holmes S; Blish CA; Front Cell Infect Microbiol; 2022; 12():757846. PubMed ID: 35223535 [TBL] [Abstract][Full Text] [Related]
20. Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56 Zulu MZ; Naidoo KK; Mncube Z; Jaggernath M; Goulder PJR; Ndung'u T; Altfeld M; Thobakgale CF AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1205-1213. PubMed ID: 28810810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]